NEJM
Mass General Researchers Encouraged by Early Responses to Autologous Cell Therapy in Glioblastoma
Premium
Three patients receiving a new cell therapy, dubbed CARv3-TEAM-E, experienced dramatic but transient tumor regression, according to data in NEJM.
Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies
Premium
Recent Phase I trial data spurred BMS to launch a larger study of MCARH109 and inspired investigators to explore the efficacy of targeting GPRC5D and BCMA with CAR T-cell therapies.
ESMO Data in HER2-Positive Lung, Breast Cancer Bolster Daiichi Sankyo, AstraZeneca's Enhertu
Premium
Studies showed that the antibody-drug conjugate benefited HER2-mutated NSCLC patients and outperformed Genentech's T-DM1 in HER2-positive, previously treated breast cancer.
In a new study, Dana-Farber researchers and collaborators explain the myriad molecular reasons why KRAS-mutated cancers develop resistance to targeted therapy.
Researchers are increasingly arguing that the tissue-agnostic approval was too broad, and that tumor mutational burden is only a biomarker of response to immunotherapy in a handful of cancer types.